

TEST PREP: A REVIEW OF THE TESTS PROVIDERS PERFORM FOR MULTIPLE MYELOMA


JOSH EPWORTH, ARNP - UWMC

# TESTS



## BLOOD

CBC w/differential CBC w/ANC BMP Liver Studies BMP + Liver = CMP SPEP SFLC Beta 2Albumin/Lactate Dehydrogenase



# Diagnosis and Monitoring Prognosis Disease Specific Markers

#### Diagnosis

- CBC
  - Hemoglobin lvls are part of CRAB criteria.
  - ANC, PLT and H/H are monitored to determine impact of disease and negative SE of TX.
  - BMP
    - Creatinine and calcium lvls are part of CRAB criteria.
    - Creatinine is a dosing factor for many medications.
- SFLC
  - The number and ratio of abnormal free light chains are part of the MDE.


#### Prognosis

- Beta 2 Microglobulin
  - Serum marker of tumor burden (self vs. non-self)
- Albumin
  - A normal protein in blood
  - Presence of myeloma increases the level of IL-6 in blood.
  - IL-6 blocks the production of albumin
- Lactate dehydrogenase
  - An enzyme *inside* a cell that helps convert sugar into energy.
  - With cell injury orto destruction LDH is leaked into the fluid *outside* the cell.

Disease Specific Markers (Output of Plasma Cells – Not the Plasma Cells Themselves)

- SPEP
  - Electrophoresis divides proteins based on physical properties.
  - An abnormal protein will have its own consistent physical properties and form its own spike
  - Estimates the amount of the abnormal protein (M-spike)
- Immunofixation
  - Determines the particular type of abnormal immunoglobulin is in excess
- SFLC
  - Proteins produced by plasma cells (K/L) which bind to heavy chains.

### NORMAL ELECTROPHORES IS



# URINE

Urine Protein Electrophoresis Bence Jones



Urine Protein Electrophoresis (UPEP) - 24hr Urine

• Determines the *amount* of monoclonal protein produced in the marrow, then excreted into the blood and excreted through the kidneys into urine.

Urine Immunofixation (UIFE) – 24hr Urine

• Determines the <u>type</u> of protein that is of monoclonal protein produced in the marrow, then excreted into the blood and excreted through the kidneys into urine

**Bence Jones Proteins** 

• A type of monoclonal protein found in urine that is produced by abnormal plasma cells in marrow.





Henry Bence Jones

# IMAGING

XR/OS MRI PET CT (HS)WBLDCT











# X-Ray

The osseous survey was a whole-body x-ray that was the gold standard for decades to assess multiple myeloma's impact on the skeleton.

#### Pros

- Inexpensive and widely available.
- Quick to schedule
- Quick to get results
- Excellent at detecting gross lesions or fractures
- Low radiation

#### <u>Cons</u>

- Misses approximately 30% of subtle lytic lesions
- Lytic lesions are only detectable if >30% of trabecular bone is destroyed.

#### Conclusion:

Single x-rays are good for quickly trying to detect an acute fracture or morethan-subtle lytic lesion. The osseous survey is not an ideal imaging system for disease diagnosis.



# MRI (noncontrast)

Magnetic resonance imaging (MRI) creates very detailed images of the human body.

#### <u>Pros</u>


- No radiation
- Ideal for initial evaluation of single plasmacytoma in bone (osseous) of the spine or pelvis as well as spinal cord and nerve roots (compressions).
- Good at discerning between smoldering and true multiple myeloma.
- A good scanning option if CT is not available.
- Very sensitive at detecting marrow infiltration, lesions and differentiate between normal and abnormal marrow.

#### <u>Cons</u>

- Cannot identify level of disease activity.
- Longs scanning time and uncomfortable for certain patients.

#### Conclusion:

Excellent for detecting very subtle lytic lesions (good for diagnosis) and detecting abnormalities in spine and pelvis.



# PET/CT PET/MRI

A combined test using a radiotracer (radioactive sugar – see SUV levels) to detect level of disease activity with the fine depiction of boney structures and lesions.

#### <u>Pros</u>


- Highly sensitive for diagnosis/staging/response/relapse.
- Gets both structural and metabolic information.
- Highly sensitive and can detect isolated lesions.

#### <u>Cons</u>

- Radiation
- Use of growth factors can impact results.
- Expensive Can be difficult to get cleared with certain insurance plans.

#### Conclusion:

A very sensitive test that can be used in a host of situations.



# (HS)WBLDCT

The newest method of imaging for MM. Used to identify bone damaging (osteolytic) lesions in the entire skeleton.

#### <u>Pros</u>

- Highly sensitive for diagnosis/staging/response/relapse.
- Does not require contrast.
- Low radiation
- Highly available (in theory)
- Fast, more comfortable than MRI

#### <u>Cons</u>

- Doesn't give levels of metabolic activity.
- Not as sensitive as MRI.
- Requires specialized training for radiology staff.


#### **Conclusion:**

A very sensitive test that can be used in a host of situations. Low cost and highly sensitive.

# MARROW

#### Aspirate/Marrow

Hematopathology Flow cytometry Cytogenetics MRD by NGS



Some quick notes about sedation:


1. Everyone gets lidocaine or a similar local anesthetic. If you only receive lidocaine this is called **NO SEDATION**.

2. If you receive an opioid based pain reliever (i.e. oxycodone) or an antianxiety medication (i.e. Ativan) at the procedure suite before the procedure this is **MINIMAL SEDATION**. You cannot receive both medications together any longer.

3. **CONSCIOUS SEDATION** is where you receive IV fentanyl (a synthetic opioid) <u>and an IV anti-anxiety (i.e. midazolam)</u>. The goal is <u>not</u> to put the patient to sleep but just to make it hard to remember the procedure. Like a COLO.


4. **GENERAL ANESTHESIA** is like surgery. The patient is unconscious during the procedure.

NOTE: The more anesthesia required the longer it takes to schedule.




**Aspirate**: The liquid portion of the procedure. Fluid that surrounds the trabeculae is drawn out. This takes cells and pieces of trabeculae with it. Drawn from inside the bone.

**Marrow**: A core sample that begins on the surface of the bone and extends into the trabecular area.




#### Hematopathology:


A microscopic review of the material from a bone marrow aspirate/biopsy. A laboratory technician looks at a slide of marrow material and counts the number of abnormal plasma cells they see. It is given in a percentage (For example: 30% abnormal plasma cells).



Flow Cytometry: Collected cells receive a bath of light sensitive dye and are passed one at a time through a beam of light. Based on how the stained cells respond to the light help identify the characteristics of the cell.




**Cytogenetics:** A test to determine the unique genetic makeup of a patient's multiple myeloma. It identifies high-risk cytogenetics as well as genetic abnormalities that will help guide treatment and inform prognosis.




#### MRD by NGS:

Minimal Residual Disease by Next Generation Sequencing



Minimal Residual Disease: Is a measurement of the remaining detectable disease *after* treatment.

**Next Generation Sequencing**: A fast, accurate method of determining the level of minimal residual disease using the unique DNA sequence of a patient's cancer.




Each B-cell has a unique structure that makes it different from other B-cells.


CDR3 is the region in DNA where each of these unique arrangements occur.


With MM the abnormal B-cells have their own unique CDR3 area rearrangement.


NGS uses this unique CDR3 sequence to identify the level of a patient's response to treatment.





Simply put, the lower the amount of this unique arrangement we find, the deeper the response to treatment.















#### The number of times we find

Tells us how much disease is left.

What do we do with this information?



# DIAGNOSIS, TREATMENT, DETERMINATION AND DURABILITY OF RESPONSE ALL DEPEND ON THESE TESTS



# QUESTIONS?